This paper demonstrates that the profilin1 model recapitulates key ALS features and can be used as an effective tool for testing ALS treatments.

ALS TDI is working with several industry and academic partners to discover new biomarkers for ALS through the ALS Research Collaborative (ARC). Currently, these efforts have led to the development of five prototype digital biomarkers.

In early June 2025, Timm Fenton set out to cross the country by bike while raising funds for the ALS Therapy Development Institute (ALS TDI) in an effort he is calling Pedals vs. ALS.

In anticipation of this year’s ALS Walk for Research, we’re interviewing the leaders of some of the event’s biggest and most successful teams. Today, we’re joined by Cory Fanelli of the team Chip Fanelli Fan Club.

The ALS Therapy Development Institute (ALS TDI) is proud to announce that a collection of cells derived from ALS patient-derived induced pluripotent stem cell (iPSC) lines will now be made widely available to researchers around the world.

The ALS Therapy Development Institute (ALS TDI) is pleased to announce its acceptance as a member of DataCite, a leading global organization dedicated to ensuring research is openly available and accessible across scientific disciplines. This partnership will significantly enhance the discoverability, accessibility, and citability of the ALS Research Collaborative (ARC) dataset, a vital resource in the global search for effective ALS treatments.